THE SOUTH AFRICAN
DEPRESSION AND ANXIETY
GROUP

facebooktwitter

Contact A Counsellor

counsellor button

KNOW MORE

panic anxiety icon

panic anxiety icon

IN THE WORKPLACE

Research on Depression in the Workplace.

For more information please click here

business

SADAG NEWSLETTER

email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here

MHM JOURNAL

Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 7 Issue1 small

Click here for more info

JOURNALISTS

journalists crew making newspaper

If you are a journalist writing a story contact Cassey or Kayla or Tracy on 011 234 4837 office@anxiety.org.za

SPEAKING BOOKS

cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

New study aims to improve long-term treatment for patients with bipolar disorder
NewYork-Presbyterian/Weill Cornell participates in federally funded multicenter study


NEW YORK (May 23, 2011) -- Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications -- quetiapine (Seroquel), a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center is one of 10 sites nationally -- and the only site in the greater New York metropolitan area -- participating in the CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness) study. The research is funded by a $10 million grant from the U.S. Agency for Healthcare Research Quality (AHRQ).

"Antipsychotic drugs have long been known to be useful for the treatment of bipolar disorder, but neurological side effects and toxicity have limited their long-term use. The good news is that the newer-generation antipsychotic drugs like quetiapine appear to be effective while having fewer neurological side effects," says Dr. James H. Kocsis, site principal investigator, director of the Payne Whitney Affective Disorders Research Clinic at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and professor of psychiatry at Weill Cornell Medical College. "In this context, it is important that we compare the relative utility of the old-fashioned mood stabilizers like lithium and the newer second-generation antipsychotic drugs -- with the ultimate goal of improving long-term treatment for patients with bipolar disorder."

Researchers will follow 480 patients with bipolar disorder randomized to one of the two medications over a six-month period. Participants can continue taking other prescriptions, such as antidepressants, as long as they are not antipsychotic drugs. Often patients with bipolar disorder need three medications to feel well, explains Dr. Kocsis.
Bipolar disorder is a lifelong, chronic and highly recurrent mood disorder characterized by episodes of mania that alternate with episodes of major depression. Symptoms can negatively affect personal relationships, job or school performance, and may result in suicide.

The study is coordinated through the Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program. The lead principal investigator is Dr. Andrew A. Nierenberg, director of the MGH Bipolar Research Program.
The AHRQ grant is part of an investment made under the American Recovery and Reinvestment Act of 2009, which designated $1.1 billion to support patient-centered outcomes research. This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.

 

Our Sponsors

Our Partners